Minor changes to the recommendations have been made in line with NICE's current wording style. See Changes after publication for more information.
1.1 Teriflunomide is recommended as an option for treating adults with active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if
they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis and
the manufacturer provides teriflunomide with the discount agreed in the patient access scheme.
1.2 People currently receiving treatment initiated within the NHS with teriflunomide that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.